Compare Mesoblast Limited (MESO) vs Pinterest Inc (PINS) Price & Performance

MESO trades at $16.9, up 1.32% on the day, with a bullish technical signal from moving averages. The company reported Ryoncil net revenues of $36 million for the quarter ended June 30, 2026, and achieved its target of 300 patients in a Phase 3 trial for chronic low back pain. Despite strong revenue growth from its commercial launch, fundamentals show a net income margin of -144.33% and negative EBITDA of $80.06 million for 2025, reflecting significant losses amid expansion.

The outlook hinges on commercial execution and regulatory progress, with analyst consensus leaning buy (45% buy ratings). Key risks include high cash burn, dependence on pipeline success, and competitive pressures. Upside potential exists if revenue growth accelerates and losses narrow, but investors face volatility from clinical trial outcomes and funding needs.

Pinterest (PINS) trades at $22.90, down 6.03% over 24 hours, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 EPS of $0.43, beating estimates of $0.36, driven by 18% revenue growth and record monthly active users. However, the stock faces pressure from lukewarm Q3 revenue guidance and competitive ad market concerns.

The outlook remains positive with strong analyst support—54% recommend Buy—and a $28.69 consensus price target implying 25% upside. Key risks include intense advertising competition and potential growth deceleration, but fundamentals are solid with revenue climbing to $4.22B in 2025 and a robust 79.47% gross margin.